Table 3 Cost-effectiveness results from the health system and societal perspectives
From: Cost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China
| Â | Cost ($) | Incremental Cost (\(\Delta\)$) | Effectiveness (QALYs) | Incremental Effectiveness (\(\Delta\) QALY) | ICER (\(\Delta\)$/\(\Delta\) QALY) |
|---|---|---|---|---|---|
1. Health system perspective | |||||
  No screening | 0 | - | 16.59 | - | - |
  AI screening | 180.19 | 180.19 | 16.76 | 0.16 | 1,107.63 |
  Ophthalmologist screening | 215.05 | 34.86 | 16.71 | -0.04 | Dominated |
2. Societal perspective | |||||
  No screening | 0 | - | 16.59 | - | - |
  AI screening | 1,683.23 | 1,683.23 | 16.76 | 0.16 | 10,347.12 |
  Ophthalmologist screening | 1,775.48 | 92.25 | 16.71 | -0.04 | Dominated |